Browsing by author "Selfe, Joanna"
Now showing items 1-19 of 19
-
ATR Is a Therapeutic Target in Synovial Sarcoma.
Jones, SE; Fleuren, EDG; Frankum, J; Konde, A; Williamson, CT; et al. (AMER ASSOC CANCER RESEARCH, 2017-12-15)Synovial sarcoma (SS) is an aggressive soft-tissue malignancy characterized by expression of SS18-SSX fusions, where treatment options are limited. To identify therapeutically actionable genetic dependencies in SS, we ... -
Biological Role and Clinical Implications of MYOD1L122R Mutation in Rhabdomyosarcoma
Chisholm, J; Shipley, J; Selfe, J (MDPI AG, 2023-03-07) -
Biological Role and Clinical Implications of MYOD1L122R Mutation in Rhabdomyosarcoma.
Di Carlo, D; Chisholm, J; Kelsey, A; Alaggio, R; Bisogno, G; et al. (MDPI, 2023-03-07)Major progress in recent decades has furthered our clinical and biological understanding of rhabdomyosarcoma (RMS) with improved stratification for treatment based on risk factors. Clinical risk factors alone were used to ... -
Chemosensitivity profiling of osteosarcoma tumour cell lines identifies a model of BRCAness.
Holme, H; Gulati, A; Brough, R; Fleuren, EDG; Bajrami, I; et al. (NATURE PUBLISHING GROUP, 2018-07-13)Osteosarcoma (OS) is an aggressive sarcoma, where novel treatment approaches are required. Genomic studies suggest that a subset of OS, including OS tumour cell lines (TCLs), exhibit genomic loss of heterozygosity (LOH) ... -
Dual blockade of the PI3K/AKT/mTOR (AZD8055) and RAS/MEK/ERK (AZD6244) pathways synergistically inhibits rhabdomyosarcoma cell growth in vitro and in vivo.
Renshaw, J; Taylor, KR; Bishop, R; Valenti, M; De Haven Brandon, A; et al. (AMER ASSOC CANCER RESEARCH, 2013-08-05)PURPOSE: To provide rationale for using phosphoinositide 3-kinase (PI3K) and/or mitogen-activated protein kinase (MAPK) pathway inhibitors to treat rhabdomyosarcomas, a major cause of pediatric and adolescent cancer deaths. ... -
Endo180 (MRC2) Antibody-Drug Conjugate for the Treatment of Sarcoma.
Evans, RJ; Perkins, DW; Selfe, J; Kelsey, A; Birch, GP; et al. (AMER ASSOC CANCER RESEARCH, 2023-02-01)Although the 5-year survival rates for sarcoma patients have improved, the proportion of patients relapsing after first-line treatment remains high, and the survival of patients with metastatic disease is dismal. Moreover, ... -
Endosialin expression in soft tissue sarcoma as a potential marker of undifferentiated mesenchymal cells.
Thway, K; Robertson, D; Jones, RL; Selfe, J; Shipley, J; et al. (NATURE PUBLISHING GROUP, 2016-08-09)BACKGROUND: Soft tissue sarcomas are a group of neoplasms with differentiation towards mesenchymal tissue, many of which are aggressive and chemotherapy resistant. Histology and immunoprofiles often overlap with neoplasms ... -
FGF7-FGFR2 autocrine signaling increases growth and chemoresistance of fusion-positive rhabdomyosarcomas.
Milton, CI; Selfe, J; Aladowicz, E; Man, SYK; Bernauer, C; et al. (WILEY, 2021-11-30)Rhabdomyosarcomas are aggressive pediatric soft-tissue sarcomas and include high-risk PAX3-FOXO1 fusion-gene-positive cases. Fibroblast growth factor receptor 4 (FGFR4) is known to contribute to rhabdomyosarcoma progression; ... -
Genomic and Epigenetic Changes Drive Aberrant Skeletal Muscle Differentiation in Rhabdomyosarcoma.
Pomella, S; Danielli, SG; Alaggio, R; Breunis, WB; Hamed, E; et al. (MDPI, 2023-05-18)Rhabdomyosarcoma (RMS), the most common soft-tissue sarcoma in children and adolescents, represents an aberrant form of skeletal muscle differentiation. Both skeletal muscle development, as well as regeneration of adult ... -
Genomic Classification and Clinical Outcome in Rhabdomyosarcoma: A Report From an International Consortium.
Shern, JF; Selfe, J; Izquierdo, E; Patidar, R; Chou, H-C; et al. (LIPPINCOTT WILLIAMS & WILKINS, 2021-09-10)PURPOSE: Rhabdomyosarcoma is the most common soft tissue sarcoma of childhood. Despite aggressive therapy, the 5-year survival rate for patients with metastatic or recurrent disease remains poor, and beyond PAX-FOXO1 fusion ... -
Germline and Somatic Genetic Variants in the p53 Pathway Interact to Affect Cancer Risk, Progression, and Drug Response.
Zhang, P; Kitchen-Smith, I; Xiong, L; Stracquadanio, G; Brown, K; et al. (AMER ASSOC CANCER RESEARCH, 2021-04-01)Insights into oncogenesis derived from cancer susceptibility loci (SNP) hold the potential to facilitate better cancer management and treatment through precision oncology. However, therapeutic insights have thus far been ... -
IGF signalling in germ cells and testicular germ cell tumours: roles and therapeutic approaches.
Selfe, J; Shipley, JM (WILEY, 2019-07-01)The insulin-like growth factor (IGF) axis plays key roles in normal tissue growth and development as well as in the progression of several tumour types and their subsequent growth and progression to a metastatic phenotype. ... -
IGF1R signalling in testicular germ cell tumour cells impacts on cell survival and acquired cisplatin resistance.
Selfe, J; Goddard, NC; McIntyre, A; Taylor, KR; Renshaw, J; et al. (WILEY, 2018-02-01)Testicular germ cell tumours (TGCTs) are the most frequent malignancy and cause of death from solid tumours in the 20- to 40-year age group. Although most cases show sensitivity to cis-platinum-based chemotherapy, this is ... -
Impact of fusion gene status versus histology on risk-stratification for rhabdomyosarcoma: Retrospective analyses of patients on UK trials.
Selfe, J; Olmos, D; Al-Saadi, R; Thway, K; Chisholm, J; et al. (WILEY, 2017-07-01)BACKGROUND: Long-term toxicities from current treatments are a major issue in paediatric cancer. Previous studies, including our own, have shown prognostic value for the presence of PAX3/7-FOXO1 fusion genes in rhabdomyosarcoma ... -
MicroRNA and gene co-expression networks characterize biological and clinical behavior of rhabdomyosarcomas.
Missiaglia, E; Shepherd, CJ; Aladowicz, E; Olmos, D; Selfe, J; et al. (ELSEVIER IRELAND LTD, 2017-01-28)Rhabdomyosarcomas (RMS) in children and adolescents are heterogeneous sarcomas broadly defined by skeletal muscle features and the presence/absence of PAX3/7-FOXO1 fusion genes. MicroRNAs are small non-coding RNAs that ... -
Molecular testing of rhabdomyosarcoma in clinical trials to improve risk stratification and outcome: A consensus view from European paediatric Soft tissue sarcoma Study Group, Children's Oncology Group and Cooperative Weichteilsarkom-Studiengruppe.
Hettmer, S; Linardic, CM; Kelsey, A; Rudzinski, ER; Vokuhl, C; et al. (ELSEVIER SCI LTD, 2022-09-01)Rhabdomyosarcomas (RMSs) are the most common soft tissue sarcomas in children/adolescents less than 18 years of age with an annual incidence of 1-2/million. Inter/intra-tumour heterogeneity raise challenges in clinical, ... -
Role for the Histone Demethylase KDM4B in Rhabdomyosarcoma via CDK6 and CCNA2: Compensation by KDM4A and Apoptotic Response of Targeting Both KDM4B and KDM4A.
Walters, ZS; Aladowicz, E; Villarejo-Balcells, B; Nugent, G; Selfe, JL; et al. (MDPI, 2021-04-06)Histone demethylases are epigenetic modulators that play key roles in regulating gene expression related to many critical cellular functions and are emerging as promising therapeutic targets in a number of tumor types. We ... -
The Hippo transducer YAP1 transforms activated satellite cells and is a potent effector of embryonal rhabdomyosarcoma formation.
Tremblay, AM; Missiaglia, E; Galli, GG; Hettmer, S; Urcia, R; et al. (CELL PRESS, 2014-08-11)The role of the Hippo pathway effector YAP1 in soft tissue sarcomas is poorly defined. Here we report that YAP1 activity is elevated in human embryonal rhabdomyosarcoma (ERMS). In mice, sustained YAP1 hyperactivity in ... -
The long non-coding RNA MYCNOS-01 regulates MYCN protein levels and affects growth of MYCN-amplified rhabdomyosarcoma and neuroblastoma cells.
O'Brien, EM; Selfe, JL; Martins, AS; Walters, ZS; Shipley, JM (BIOMED CENTRAL LTD, 2018-02-21)BACKGROUND: MYCN is amplified in small cell lung cancers and several pediatric tumors, including alveolar rhabdomyosarcomas and neuroblastomas. MYCN protein is known to play a key oncogenic role in both alveolar rhabdomyosarcomas ...